However, levels of P-ERK-1/2 in CLL B-cells mostly remain reduced in ibrutinib exposed patients over time compared to their respective baseline (pre-ibrutinib) samples (Figure 3B). The gene discussed is MAPK3; the disease is B-cell chronic lymphocytic leukemia.